Biotechnology Contract Manufacturing Market 2026-2032: Biologics CDMO Services for mAbs, Cell Therapy & ADCs – 8.8% CAGR

Executive Summary: Solving Biologics Manufacturing Complexity Through Strategic Outsourcing

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biotechnology Contract Manufacturing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. For biopharmaceutical companies, emerging biotech firms, and pharmaceutical R&D leaders, bringing biologic drugs to market presents persistent manufacturing challenges that differ fundamentally from traditional small-molecule pharmaceuticals. Biologics—monoclonal antibodies, cell therapies, gene therapies, and vaccines—require specialized production capabilities including mammalian cell culture (CHO cells, HEK293), strict aseptic processing, complex purification trains (protein A chromatography, viral inactivation), and regulatory compliance with current Good Manufacturing Practices (cGMP). The capital investment for a single biologic manufacturing facility exceeds US$ 500 million, with construction timelines of 4-6 years. Biotechnology contract manufacturing addresses these barriers by providing established infrastructure, technical expertise, and regulatory know-how, enabling biotech innovators to focus on discovery and clinical development while outsourcing production to specialized contract development and manufacturing organizations (CDMOs).

Based on current market conditions, historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global biotechnology contract manufacturing market, including market size, share, demand, industry development status, and forecasts for the next several years. The global market was valued at US$ 19,190 million in 2025 and is projected to reach US$ 34,370 million by 2032, growing at a robust compound annual growth rate (CAGR) of 8.8% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5739186/biotechnology-contract-manufacturing

Market Drivers: The Biologics Pipeline Expansion

The increasing popularity of biologics in medicine has led to a significant rise in outsourcing manufacturing for biotechnology contract manufacturing services. Biologics contract manufacturers possess the know-how and infrastructure to produce these complex therapies effectively while ensuring compliance with strict quality regulations from the FDA, EMA, and other global health authorities.

According to Statista, there were more than 21,000 drugs in the global R&D pipeline in 2023, with biologics representing an increasing proportion of late-stage candidates. Furthermore, the FDA approved 71 new drugs in 2023; of these approvals, 48% were biologics—the highest percentage in history, up from 32% in 2020. This trend reflects the industry’s shift from small-molecule drugs toward large-molecule biologics for treating cancer, autoimmune diseases, and rare genetic disorders.

The demand for biotechnology contract manufacturing services is expected to be highest among smaller biotech companies that hold intellectual property rights for novel biologics but lack internal manufacturing capacity. These virtual biotech firms and emerging players typically operate with 10-50 employees focused on discovery and clinical trial management, making outsourcing to CDMOs the only viable path to commercialization. A representative user case from Q1 2026 involved a California-based gene therapy startup with a promising AAV-based treatment for inherited retinal disease. The company engaged Lonza for biotechnology contract manufacturing of its clinical trial material, leveraging Lonza’s existing viral vector platform to achieve first-in-human studies in 14 months—a timeline the startup estimated would require 36+ months and US$ 200+ million for internal facility development.

Industry Development Characteristics: Technological Innovation and Strategic Partnerships

The biotechnology contract manufacturing market is characterized by continuous innovation in production methodologies. This has led to the incorporation of cutting-edge production methods like continuous manufacturing and single-use technologies aimed at enhancing operational efficiency and adaptability for biotechnology contract manufacturing providers.

Continuous manufacturing, as opposed to traditional fed-batch processing, enables steady-state production of biologics over extended periods (weeks rather than days), increasing volumetric productivity by 30-50% and reducing facility footprint. A technical development from February 2026: WuXi Biologics announced the first regulatory approval for a monoclonal antibody produced entirely via continuous biotechnology contract manufacturing from the China National Medical Products Administration (NMPA), validating continuous processing for commercial biologics production.

Single-use technologies (disposable bioreactors, tubing assemblies, storage bags) have become standard in biotechnology contract manufacturing for clinical and commercial production up to 2,000L scale. These systems eliminate cleaning validation requirements (a significant regulatory burden for stainless steel equipment), reduce cross-contamination risk, and enable faster campaign changeover. Leading CDMOs including Thermo Fisher Scientific and Samsung Biologics have invested in single-use facilities with 12-24 week construction timelines versus 48+ months for traditional stainless steel plants.

Partnerships and collaborations between pharmaceutical firms and contract manufacturing organizations are increasing for biologic drug product manufacturing, allowing for the modification of manufacturing processes and cost-effective solutions within biotechnology contract manufacturing agreements. A policy development from March 2026: The FDA’s updated guidance on contract manufacturing arrangements clarifies quality agreement requirements for biotechnology contract manufacturing partnerships, including defined responsibilities for deviation investigations, change control, and lot release testing. This regulatory clarity has accelerated CDMO engagement, with several large pharma companies (Pfizer, Roche, Novartis) announcing expanded biotechnology contract manufacturing partnerships in Q1-Q2 2026.

Market Segmentation by Service Type: Drug Substance vs. Drug Product Manufacturing

The biotechnology contract manufacturing market is segmented by service type into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing.

Biologic Drug Substance Manufacturing

Biologic drug substance manufacturing encompasses upstream processing (cell culture, fermentation, cell line development) and downstream processing (purification, viral inactivation, ultrafiltration) to produce the active biologic ingredient. This segment represents approximately 65% of biotechnology contract manufacturing revenue, reflecting the technical complexity and capital intensity of biologic production. Drug substance manufacturing requires specialized capabilities including high-titer CHO cell expression systems (achieving 5-10 g/L yields in modern facilities), protein A chromatography for mAb purification, and viral clearance validation. A technical challenge unique to drug substance manufacturing is capacity allocation; leading CDMOs operate with 90-95% utilization rates, requiring clients to reserve capacity 12-24 months in advance.

Biologic Drug Product Manufacturing

Biologic drug product manufacturing encompasses aseptic filling, lyophilization (freeze-drying), labeling, and packaging of the final dosage form (vials, prefilled syringes, cartridges). This segment is growing at a faster CAGR (9.5% vs. 8.5% for drug substance) as more biologic candidates advance from clinical trials to commercial approval. An exclusive industry observation from Q2 2026 reveals a divergence in biotechnology contract manufacturing requirements between monoclonal antibodies and cell/gene therapies. For mAbs, drug product manufacturing is relatively standardized, with high-speed filling lines (400+ vials per minute) and established lyophilization cycles. For cell and gene therapies, drug product manufacturing requires cryopreservation (-150°C to -196°C storage), specialized cryobags or vials, and chain-of-identity documentation for patient-specific products—capabilities that only a subset of biotechnology contract manufacturing providers offer.

Market Segmentation by Application: mAbs, Cell & Gene Therapy, ADCs, Vaccines, and Peptides/Proteins

Monoclonal Antibodies

Monoclonal antibodies (mAbs) represent the largest application segment for biotechnology contract manufacturing, accounting for approximately 55% of market revenue. mAbs are used to treat oncology (Keytruda, Opdivo), autoimmune diseases (Humira, Stelara), and infectious diseases. The technical maturity of mAb manufacturing—standardized platforms, well-characterized cell lines, established regulatory pathways—makes them the core business for most biotechnology contract manufacturing providers.

Cell Therapy & Gene Therapy

Cell therapy (CAR-T, TCR-T) and gene therapy (AAV, lentiviral, non-viral) represent the fastest-growing application segment for biotechnology contract manufacturing, with projected CAGR of 18-22% from 2026 to 2032. These personalized therapies present unique manufacturing challenges: patient-specific starting materials (leukapheresis products), short shelf lives (48-72 hours for some cell therapies), and complex supply chain logistics. A representative user case from Q4 2025 involved a cell therapy company with an approved CAR-T product requiring manufacturing capacity expansion. The company engaged Catalent and FUJIFILM Diosynth Biotechnologies for biotechnology contract manufacturing, leveraging their decentralized manufacturing network with facilities in the US, Europe, and Asia to serve patients globally. The partnership reduced vein-to-infusion time from 28 days to 18 days by enabling manufacturing at the facility nearest to each patient’s treatment center.

Antibody-Drug Conjugates (ADCs)

ADCs combine a monoclonal antibody with a cytotoxic drug via a chemical linker, requiring biotechnology contract manufacturing capabilities for both biologic (antibody) and small-molecule (payload) production, plus conjugation chemistry. This complexity drives premium pricing, with ADC manufacturing costs typically 30-50% higher than mAb-only production. A technical challenge unique to ADCs is linker-payload stability during conjugation and subsequent formulation; leading CDMOs including Lonza and AbbVie have developed proprietary conjugation platforms with optimized reaction conditions and analytical methods to ensure drug-to-antibody ratio (DAR) consistency.

Vaccines

Vaccine biotechnology contract manufacturing encompasses traditional protein-based vaccines, viral vector vaccines (COVID-19), and mRNA vaccines. The mRNA vaccine platform, validated during the pandemic, requires specialized lipid nanoparticle (LNP) encapsulation capabilities. A policy development from January 2026: The World Health Organization’s mRNA Technology Transfer Programme expanded to include 15 low- and middle-income country manufacturers, with biotechnology contract manufacturing training and technology transfer from established CDMOs to build regional pandemic preparedness capacity.

Therapeutic Peptides & Proteins

This segment includes therapeutic peptides (GLP-1 agonists for diabetes/obesity, including semaglutide and tirzepatide) and recombinant proteins (enzymes, growth factors, cytokines). The explosive growth of GLP-1 drugs has created unprecedented demand for biotechnology contract manufacturing capacity, with CDMOs adding dedicated peptide synthesis and purification lines.

Competitive Landscape

The biotechnology contract manufacturing market features a concentrated landscape of global CDMOs. Key players identified in the full report include: Lonza, Thermo Fisher Scientific, Inc., Catalent, Inc., Samsung Biologics, WuXi Biologics, Boehringer Ingelheim International GmbH, FUJIFILM Holding Corporation, AbbVie, Inc., Eurofins Scientific, AGC, Inc., and Merck KGaA.

Contact Us:

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp